Drug Development.

Area of Science:

• Neurology
• Geriatrics
• Pharmacology

Background:

• Secondary analysis of the CLARITY-AD trial indicated lecanemab may reduce burden in care partners (CP) and improve quality of life for persons living with dementia (PLWD).
• This pilot study explores CP outcomes within a registry of PLWD receiving lecanemab infusions.

Purpose of the Study:

• To investigate the experiences and outcomes of care partners (CP) of persons living with dementia (PLWD) undergoing lecanemab infusions.
• To assess caregiver burden, sleep quality, and overall experience of CP during the initial phase of lecanemab treatment.

Main Methods:

• PLWD and their CP were enrolled prior to lecanemab infusions.
• CP completed self-reported measures (Pittsburgh Sleep Quality Index, Zarit Burden Interview) at baseline and 3 months.
• Semi-structured interviews were conducted at 3 months to gather qualitative data on CP and PLWD experiences.

Main Results:

• Ten CP were enrolled; 60% were male, 100% were spouses, with a mean age of 70.6 years.
• At 3 months, no increase in CP burden was observed, with 50% reporting reduced burden.
• Sleep quality showed improvement in some CP, though 67% still exhibited poor sleep efficiency. All participants recommended the infusions.

Conclusions:

• Lecanemab infusions were well-accepted by CP and PLWD, with positive overall experiences reported after 3 months.
• The treatment did not appear to increase caregiver burden.
• Ongoing data collection will provide further insights into long-term CP outcomes.